Chiral Bifunctional Sulfide-Catalyzed Enantioselective Synthesis of α-Substituted γ-Lactones Bearing a γ-Quaternary Stereocenter

Abstract

Catalytic highly enantioselective syntheses of α-spiro-γ-lactones and α-substituted γ-lactones bearing a γ-quaternary stereocenter have been achieved through chiral bifunctional sulfide-catalyzed asymmetric bromolactonizations. The synthetic utility of the optically active γ-lactone products was demonstrated by transformations into functionalized γ-lactones and epoxides possessing a quaternary stereocenter.

Key words

asymmetric synthesis - halogenation - lactones - organocatalysis - sulfides - bromolactonization

Publication History

Received: 13 July 2023

Accepted after revision: 29 August 2023

Accepted Manuscript online:
29 August 2023

Article published online:
19 October 2023

• References and Notes

• 1a Castellanos A, Fletcher SP. Chem. Eur. J. 2011; 17: 5766
• 1b Denmark SE, Kuester WE, Burk MT. Angew. Chem. Int. Ed. 2012; 51: 10938
• 1c Hennecke U. Chem. Asian J. 2012; 7: 456
• 1d Tan CK, Yeung Y.-Y. Chem. Commun. 2013; 49: 7985
• 1e Zheng S, Schienebeck CM, Zhang W, Wang H.-Y, Tang W. Asian J. Org. Chem. 2014; 3: 366
• 1f Cheng YA, Yu WZ, Yeung Y.-Y. Org. Biomol. Chem. 2014; 12: 2333
• 1g Tripathi CB, Mukherjee S. Synlett 2014; 25: 163
• 1h Hennecke U, Wilking M. Synlett 2014; 25: 1633
• 1i Nolsøe JM. J, Hansen TV. Eur. J. Org. Chem. 2014; 3051
• 1j Sakakura A, Ishihara K. Chem. Rec. 2015; 15: 728
• 1k Gieuw MH, Ke Z, Yeung Y.-Y. Chem. Rec. 2017; 17: 287
• 1l Luo J, Liu X, Zhao X. Synlett 2017; 28: 397
• 1m Kawato Y, Hamashima Y. Synlett 2018; 29: 1257
• 1n Kristianslund R, Tungen JE, Hansen TV. Org. Biomol. Chem. 2019; 17: 3079
• 1o Ashtekar KD, Jaganathan A, Borhan B, Whitehead DC. Org. React. 2021; 105: 1
• 1p Liao L, Zhao X. Acc. Chem. Res. 2022; 55: 2439
• 1q Liu S, Zhang B.-Q, Xiao W.-Y, Li Y.-L, Deng J. Adv. Synth. Catal. 2022; 364: 3974
• 1r Nishiyori R, Mori T, Okuno K, Shirakawa S. Org. Biomol. Chem. 2023; 21: 3263
• 1s Egami H, Hamashima Y. Chem. Rec. 2023; 23: e202200285
• 2a Nishiyori R, Tsuchihashi A, Mochizuki A, Kaneko K, Yamanaka M, Shirakawa S. Chem. Eur. J. 2018; 24: 16747
• 2b Tsuchihashi A, Shirakawa S. Synlett 2019; 30: 1662
• 2c Nakamura T, Okuno K, Kaneko K, Yamanaka M, Shirakawa S. Org. Biomol. Chem. 2020; 18: 3367
• 2d Okuno K, Nakamura T, Shirakawa S. Asian J. Org. Chem. 2021; 10: 655
• 2e Okuno K, Hiraki M, Bun C, Shirakawa S. Bull. Chem. Soc. Jpn. 2022; 95: 52
• 3a Okada M, Kaneko K, Yamanaka M, Shirakawa S. Org. Biomol. Chem. 2019; 17: 3747
• 3b Nishiyori R, Maynard JR. J, Shirakawa S. Asian J. Org. Chem. 2020; 9: 192
• 3c Nishiyori R, Okada M, Maynard JR. J, Shirakawa S. Asian J. Org. Chem. 2021; 10: 1444
• 3d Hiraki M, Okuno K, Nishiyori R, Noser AA, Shirakawa S. Chem. Commun. 2021; 57: 10907
• 3e Nishiyori R, Okuno K, Chan B, Shirakawa S. Chem. Pharm. Bull. 2022; 70: 599
• 3f Nishiyori R, Mori T, Shirakawa S. Org. Biomol. Chem. 2023; 21: 4002
• 3g Okuno K, Bun C, Shirakawa S. Adv. Synth. Catal. 2023; 365: 1496
• 4 Mori T, Abe K, Shirakawa S. J. Org. Chem. 2023; 88: 7830
• 5a Jarvest RL, Breen AL, Edge CM, Chaikin MA, Jennings LJ, Truneh A, Sweet RW, Hertzberg RP. Bioorg. Med. Chem. Lett. 1993; 3: 2851
• 5b Siless GE, Lozano E, Sánchez M, Mazzuca M, Sosa MA, Palermo JA. Bioorg. Med. Chem. Lett. 2013; 23: 4964
• 5c Lv H.-w, Luo J.-g, Zhu M.-d, Shan S.-m, Kong L.-y. Chem. Pharm. Bull. 2014; 62: 472
• 5d Gao R, Bhandare RR, Canney DJ. Med. Chem. Res. 2014; 23: 1023
• 5e Yuan Q.-Q, Tang S, Song W.-B, Wang W.-Q, Huang M, Xuan L.-J. J. Nat. Prod. 2017; 80: 254
• 5f Blass BE, Gao R, Blattner KM, Gordon JC, Pippin DA, Canney DJ. Med. Chem. Res. 2021; 30: 1713
• 5g Rečnik L.-M, Thatcher RJ, Mallah S, Butts CP, Collingridge GL, Molnár E, Jane DE, Willis CL. Org. Biomol. Chem. 2021; 19: 9154
• 6a Corey EJ, Guzman-Perez A. Angew. Chem. Int. Ed. 1998; 37: 388
• 6b Christoffers J, Mann A. Angew. Chem. Int. Ed. 2001; 40: 4591
• 6c Denissova I, Barriault L. Tetrahedron 2003; 59: 10105
• 6d Peterson EA, Overman LE. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 11943
• 6e Quasdorf KW, Overman LE. Nature 2014; 516: 181
• 6f Zhang X, Tan C.-H. Chem 2021; 7: 1451
• 7 Asymmetric Bromolactonization; General Procedure A solution of the appropriate substrate 2 (0.10 mmol) and catalyst (S)-1b (4.5 mg, 0.010 mmol, 10 mol %) in toluene (1.5 mL)–CH₂Cl₂ (0.5 mL) was cooled to –78 °C and stirred for 10 min at –78 °C. NBP (27.1 mg, 0.12 mmol, 1.2 equiv) was added to the cooled reaction solution and the resulting mixture was stirred for 24 h at –78 °C. The reaction was then quenched with sat. aq Na₂SO₃ (3 mL) at –78 °C and stirred for 10 min at –78 °C. The mixture was then diluted with CH₂Cl₂ (2 mL) and H₂O (2 mL) and warmed to r.t. The organic materials were extracted with CH₂Cl₂ (3 × 5 mL), and the combined extracts were dried (Na₂SO₄) and concentrated. The residue was purified by flash column chromatography (silica gel) to give product 3. The enantioselectivities of the isolated products 3 were determined by HPLC analysis on a chiral stationary phase. (3R)-3-(Bromomethyl)-3-phenyl-2-oxaspiro[4.4]nonan-1-one (3b) Colorless oil; yield: 29.1 mg (94%); [α]_D ²¹ +14.6 (c = 1.4, CHCl₃; 94:6 er). HPLC [Daicel Chiralpak IC-3, hexane–2-propanol (20:1), flow rate = 0.5 mL/min, λ = 254 nm]: t _R: 25.7 min (major); 36.8 min (minor). IR (neat): 2958, 1767, 1145, 1035, 996, 973, 767, 702 cm^–1. ¹H NMR (400 MHz, CDCl₃): δ = 7.44–7.32 (m, 5 H), 3.73 (d, J = 11.2 Hz, 1 H), 3.65 (d, J = 11.2 Hz, 1 H), 2.77 (d, J = 13.0 Hz, 1 H), 2.55 (d, J = 13.0 Hz, 1 H), 2.27–2.20 (m, 1 H), 1.89–1.50 (m, 6 H), 1.26–1.18 (m, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ = 181.2, 141.3, 128.7, 128.4, 125.0, 83.6, 50.1, 46.7, 41.1, 39.2, 38.0, 25.4, 25.2. HRMS (EI): m/z [M⁺] calcd for C₁₅H₁₇BrO₂: 308.0412; found: 308.0412. (5R)-5-(Bromomethyl)-3,3-diethyl-5-phenyldihydrofuran-2(3H)-one (3g) Colorless oil; yield: 28.0 mg (90%); [α]_D ²⁵ +9.3 (c = 1.1, CHCl₃; 97:3 er). HPLC [Daicel Chiralpak IE-3, hexane–2-propanol (20:1), flow rate = 0.5 mL/min, λ = 254 nm] t _R = 28.2 min (minor); 30.5 min (major). IR (neat): 2968, 1768, 1120, 1032, 703 cm^–1. ¹H NMR (400 MHz, CDCl₃): δ = 7.45–7.32 (m, 5 H), 3.71 (d, J = 11.2 Hz, 1 H), 3.62 (d, J = 11.4 Hz, 1 H), 2.80 (d, J = 13.3 Hz, 1 H), 2.44 (d, J = 13.5 Hz, 1 H), 1.75 (q, J = 7.6 Hz, 2 H), 1.39–1.25 (m, 2 H), 1.00 (t, J = 7.5 Hz, 3 H), 0.65 (t, J = 7.4 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 179.5, 141.8, 128.8, 128.4, 124.9, 83.0, 48.7, 42.1, 41.3, 29.2, 27.9, 8.8, 8.4. HRMS (EI): m/z [M⁺] calcd for C₁₅H₁₉BrO₂: 310.0568; found: 310.0568.
• 8 Nishikata T, Nakamura K, Itonaga K, Ishikawa S. Org. Lett. 2014; 16: 5816
• 9a Saito N, Kittaka A. ChemBioChem 2006; 7: 1478
• 9b Lepoittevin J.-P, Berl V, Giménez-Arnau E. Chem. Rec. 2009; 9: 258
• 9c Freund RR. A, Gobrecht P, Fischer D, Arndt H.-D. Nat. Prod. Rep. 2020; 37: 541
• 9d Ludwiczuk A, Asakawa Y. Nat. Prod. Commun. 2021;
• 9e Daignan Fornier S, de Saint Germain A, Retailleau P, Pillot J.-P, Taulera Q, Andna L, Miesch L, Rochange S, Pouvreau J.-B, Boyer F.-D. J. Nat. Prod. 2022; 85: 1976
• 10a Wang W, He H, Gan M, Wang H, Wang Y, Jiang X. Adv. Synth. Catal. 2019; 361: 4797
• 10b He H, Liu Z, Wang W, Jiang X. Bioorg. Med. Chem. 2020; 28: 115281
• 11 A transition-state model for the chiral bifunctional sulfide (S)-1b-catalyzed bromolactonization in the synthesis of γ-lactones bearing a γ-quaternary stereocenter is discussed in our previous report.^3c